Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 227 results

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)

RFA
Friday, October 4, 2019
Heal, Translational Research, Clinical Trials Research
Friday, September 9, 2022
R41/R42
RFA-NS-20-008
Emily Caporello

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)

RFA
Friday, October 4, 2019
Friday, September 9, 2022
R43/R44
RFA-NS-20-011
Emily Caporello

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)

RFA
Friday, October 4, 2019
Heal, Translational Research, Clinical Trials Research
Friday, September 9, 2022
R43/R44
RFA-NS-20-010

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, R44) Clinical Trial Not Allowed

PAR
Monday, August 5, 2019
Wednesday, April 6, 2022
SB1
PAR-19-334

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R and D throughout the award. Clinical trials not accepted under this FOA.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R41/R42
PAS-19-317

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R43/R44
PAS-19-316

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Innovation Research (SBIR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

PAR
Wednesday, July 10, 2019
Sunday, May 8, 2022
R61/R33
PAR-19-315

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

PAR
Wednesday, May 8, 2019
Sunday, May 8, 2022
R01
PAR-19-274

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

PAR
Wednesday, May 8, 2019
Sunday, May 8, 2022
R03
PAR-19-276
Robin Conwit

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

PAR
Wednesday, May 8, 2019
Sunday, May 8, 2022
R21
PAR-19-275

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Pages